This pilot study showed a direct molecular Lyme disease diagnostic test could be used to identify and genotype Borrelia burgdorferi during antibiotic treatment in early Lyme disease patients. Findings suggest that the host immune system or differential antibiotic susceptibility might have played a role in the observed genotypic shift.
Recognition of the EM rash is crucial to early diagnosis and treatment. Improved rash recognition using deep learning methodology to prescreen patient rash photos may help prevent later serious manifestations of Lyme disease.
This study uses a neuroimaging radiotracer with positron emission tomography (PET) to quantify cerebral glial activation in brains of patients with post-treatment Lyme disease. Results show elevated central nervous system immune activation in patients with PTLDS as compared to controls.
Lyme disease (Borrelia burgdorferi infection) is increasingly recognized as a significant worldwide illness. This study provides insights into important immune mechanisms involved in Borrelia burgdorferi clearance in human Lyme disease.
This study evaluates overall incidence rates and demographic, seasonal, and geographic trends of first Lyme disease diagnosis among 384,652 Maryland Medicaid members enrolled from July 2004-June 2011 and represents the first analysis of claims data from publicly insured individuals.
Patients with Post-treatment Lyme Disease Syndrome (PTLDS) commonly complain of cognitive symptoms. The study found, in subsets of PTLDS patients, objective evidence of cognitive decline in verbal memory and processing speed, cognitive impairment, and sub-optimal engagement with testing.
